TCG Crossover Management’s RAPT Therapeutics RAPT Stock Holding History

TCG Crossover Management’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,582,408	Closed	-$87.5M	–	52
2025 Q4	$87.5M	Buy	2,582,408 +946,133	+58%	+$29.4M	2.89%	7
2025 Q3	$42.2M	Hold	1,636,275	–	–	2.08%	15
2025 Q2	$13.1M	Hold	1,636,275	–	–	1.5%	24
2025 Q1	$16M	Sell	1,636,275 -5,633	-0.3%	-$55.4K	2.18%	20
2024 Q4	$19.8M	Buy	+1,641,908	New	+$20.9M	1.93%	24

TCG Crossover Management's RAPT Position: Q1 2026 in Review

TCG Crossover Management sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 2,582,408 shares — an estimated $87.5M sold.

TCG Crossover Management first reported a position in RAPT in Q4 2024 and held it in 5 quarters. The position peaked at $87.5M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

TCG Crossover Management reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
TCG Crossover Management sold 2,582,408 RAPT Therapeutics shares in Q1 2026, an estimated $87.5M.
TCG Crossover Management first reported a position in RAPT Therapeutics in Q4 2024 and held it in 5 quarters.
TCG Crossover Management's RAPT Therapeutics position peaked at $87.5M in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.